Table 1 Comparison of the prevalence of auto-Abs to specific sets of type I IFNs in IPF patients to that of 36,775 individuals from the general population, adjusted on age and sex
Auto-Abs neutralizing type I IFN positive (amount of type I IFNs neutralized, in plasma diluted 1:10) | OR [95% CI] | p |
|---|---|---|
Auto-Abs neutralizing IFNα2 and ω (10 ng/ml) | 0.57 [0.00–4.01] | 0.66 |
Auto-Abs neutralizing IFNα2 or ω (10 ng/ml) | 0.50 [0.06–1.81] | 0.34 |
Auto-Abs neutralizing IFNα2 (10 ng/ml) | 0.71 [0.08–2.61] | 0.66 |
Auto-Abs neutralizing IFNω (10 ng/ml) | 0.28 [0.00–1.94] | 0.26 |
Auto-Abs neutralizing IFN-β (10 ng/ml) | 2.32 [0.25–9.68] | 0.38 |
Auto-Abs neutralizing IFNα2 and ω (100 pg/ml) | 0.71 [0.08–2.63] | 0.66 |
Auto-Abs neutralizing IFNα2 or ω (100 pg/ml) | 0.54 [0.15–1.35] | 0.21 |
Auto-Abs neutralizing IFNα2 (100 pg/ml) | 0.55 [0.15–1.35] | 0.31 |
Auto-Abs neutralizing IFNω (100 pg/ml) | 0.61 [0.13–1.76] | 0.40 |